Motivimeve

Motivimeve is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). It is also used off-label to treat other conditions such as social anxiety disorder and generalized anxiety disorder. Motivimeve was approved by the U.S. Food and Drug Administration (FDA) in 2019 and is marketed under the brand name Vraylar.

The active ingredient in Motivimeve is esketamine, a Schedule III controlled substance in the United States. Esketamine is a structural analog of ketamine, another dissociative anesthetic. Unlike ketamine, esketamine is not a controlled substance in many other countries, including the United Kingdom and Australia, where it is used off-label to treat treatment-resistant depression.

Motivimeve is administered intravenously over a period of 40 minutes. The medication is typically given in a hospital or clinic setting, and patients are monitored for side effects during and after the infusion. Common side effects of Motivimeve include nausea, vomiting, dizziness, and headache. Serious side effects may include seizures, hallucinations, and changes in heart rate or blood pressure.

Motivimeve is not recommended for use in patients with a history of seizures, a personal or family history of bipolar disorder, or a history of substance abuse. It is also not recommended for use in patients with a history of psychosis or a history of suicidal thoughts or behaviors. Patients should be closely monitored for these and other potential side effects during and after treatment with Motivimeve.